Renalytix Plc (LON:RENX – Get Free Report) was down 3.4% during trading on Wednesday . The company traded as low as GBX 11 ($0.14) and last traded at GBX 11.11 ($0.14). Approximately 181,677 shares traded hands during trading, a decline of 47% from the average daily volume of 344,406 shares. The stock had previously closed at GBX 11.50 ($0.14).
Renalytix Stock Down 3.4 %
The firm has a fifty day simple moving average of GBX 9.49 and a 200-day simple moving average of GBX 10.27. The company has a market capitalization of £18.44 million, a PE ratio of -46.30 and a beta of 2.10. The company has a debt-to-equity ratio of 173.95, a quick ratio of 2.42 and a current ratio of 0.53.
Insider Buying and Selling
In other Renalytix news, insider James Renwick McCullough bought 25,000 shares of the stock in a transaction on Tuesday, December 10th. The stock was purchased at an average price of GBX 9 ($0.11) per share, for a total transaction of £2,250 ($2,769.91). Insiders own 35.74% of the company’s stock.
About Renalytix
Renalytix (LSE: RENX) (NASDAQ: RNLX) is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. The Company’s lead product is KidneyIntelX, which has been granted Breakthrough Designation by the U.S.
Recommended Stories
- Five stocks we like better than Renalytix
- 3 Small Caps With Big Return Potential
- Oracle Announces Game-Changing News for the AI Industry
- What is the NASDAQ Stock Exchange?
- Netflix Adds 19 Million Subscribers, Growth Is Far From Over
- What is the Dow Jones Industrial Average (DJIA)?
- Tempus AI: A Game-Changer in AI-Powered Healthcare
Receive News & Ratings for Renalytix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Renalytix and related companies with MarketBeat.com's FREE daily email newsletter.
